Health & Fitness
American Society of Clinical Oncology Annual Meeting 2014: Key lung cancer abstracts
Dr. MG. Kris (Professor of Medicine, Weill Cornell Medical College; Chief, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York) has summarized a number of interesting abstracts (to be presented at the American Society of Clinical Oncology Annual Meeting; see reference 10) that would be of interest to anyone wishing to keep up to date with the latest developments in lung cancer research. I have added information about bavituximab and the BATLLE-2 and GALAXY-2 trials.
Interested readers are referred to my slide deck on lung cancer research as one source of background reading.
References
Find out what's happening in Norwalkfor free with the latest updates from Patch.
1. Antonia SJ, Gettinger SN, Chow LQM et al.: Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8023. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8023).
2. Blumenthal GM, Karuri S, Khozin S et al.: Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): A meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. Food and Drug Administration (FDA). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8012. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8012).
Find out what's happening in Norwalkfor free with the latest updates from Patch.
3. Brahmer JR, Rizvi NA, Lutzky J et al.: Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8021. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8021^).
4. Garon EB, Leighl NB, Rizvi NA et al.: Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8020).
5. Gerber DE, Shah J, Keilholz U et al.: Stimulating an immune response through bavituximab in a phase III lung cancer study. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract TPS8129. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8129).
6. Janne PA, Ramalingam SS, Yang JC et al.: Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8009. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8009^); 2014.
7. Kato T, Seto T, Nishio M et al.: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8005. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8005).
8. Kelly K, Altorki NK, Eberhardt WEE et al.: A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 7501. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 7501).
9. Kim DW, Lee DH, Kang JH et al.: Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8011).
10. Kris, M. Taking Lung Cancer Treatment to the 'Next Level' [http://www.medscape.com/viewarticle/825638]
11. Lim SH, Lee JY, Lee MY et al.: Randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small cell lung cancer (NSCLC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8037. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8037).
12. Papadimitrakopoulou V., Lee JJ, Wistuba II et al.: BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8042. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8042).
13. Ramalingam SS, Zaric B., Ceric T et al.: Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract TPS8118^. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8118^).
14. Rizvi NA, Garon EB, Patnaik A et al.: Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8007. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8007).
15. Sequist LV, Soria JC, Shirish M et al.: First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8010^).
16. Thatcher N, Hirsch FR, Szczesna A et al.: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract 8008. In.: J Clin Oncol 32:5s, 2014 (suppl; abstr 8008^).
